Immix Biopharma announced a $125M offering immediately after an interim readout from its Phase 2 NEXICART-2 trial. The company reported that its BCMA-targeted CAR-T NXC-201 achieved an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis, with additional data expected as the study matures. The financing comes as Immix lines up a BLA submission next year, with final data completion timed to support regulatory review. The pairing of an interim efficacy readout with equity capital reflects how quickly market appetite can follow strong signals in difficult-to-treat hematology indications. For the CAR-T field, the report underscores the competitive focus on response depth in AL amyloidosis—where patient durability and safety profiles often determine uptake and payer and center adoption.